Skip to main content

Table 2 Phase II trials included in the analysis with the name of the author, year of publication, number of patients enrolled in the trial, the intervention that was tested and the outcome

From: Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013

Author

Year

No of patients

Intervention

Outcome for CS patients

Merimsky et al.[23]

2000

18 advanced sarcoma (3 CS)

Gemcitabine

2 SD

Skubitz et al.[24]

2003

47 advanced sarcoma (1 CS)

Pegylated-liposomal doxorubicin

Not mentioned

Nooij et al.[25]

2005

37 bone sarcoma (16 CS)

Doxorubicin + cisplatin

2 CR

Group A: operable, non-metastatic (4 CS)

3 SD

Group B: inoperable, metastatic (12 CS)

Maki et al.[26]

2009

145 advanced sarcoma (2 CS)

Sorafenib (multi-tyrosine kinase inhibitor)

Not mentioned

Pacey et al.[27]

2009

26 advanced sarcoma (2 CS)

Sorafenib(multi-tyrosine kinase inhibitor)

1 SD

Grignani et al.[28]

2011

26 advanced chondrosarcoma

Imatinib mesylate (c-kit/PDGFR inhibitor)

8 SD

OS 11 months

Fox et al.[29]

2012

53 advanced sarcoma (25 CS)

Gemcitabine + docetaxel

2 PR

Italiano et al.[30]

2012

40 advanced CS

GDC-0449/vismodegib (hedgehog inhibitor)

4 SD (of first 17 patients)

Schuetze et al.[31]

2012

49 advanced sarcoma (2 CS)

Sirolimus (mTOR inhibitor) + cyclophosphamide

1 SD

Ha et al.[32]

2013

36 advanced sarcoma

Cetuximab (EGFR antibody)

PD

Group A: EGFR+

Group B: EGFR- (1 CS)

Schwartz et al.[33]

2013

388 advanced sarcoma

Cixutumumab (IGF1R antibody) + temsirolimus (mTOR-inhibitor)

Not mentioned

Group A: IGF-1R + soft tissue sarcoma

Group B: IGF-1R + bone sarcoma (20 CS)

  

Group C: IGF-1R- sarcoma (18 CS)

  
  1. CR complete response, CS chondrosarcoma, OS overall survival, PD progressive disease, PFS progression free survival, PR partial response, SD stable disease.